Table 1.
Baseline demographic characteristics of the patients with COVID-19 at the time of admission.
| ID Patients | Discharged Alive or Died | Age | Gender | T °C | Oxygen Saturation | Respiration Rate | CT-SKAN * | Therapy | Day of Death |
|---|---|---|---|---|---|---|---|---|---|
| 38 34939 |
Dead | 66 | Male | 37.1 | 65 | 26 | 4 | Tocilizumab 400 mg CVVH 1470 min |
28 |
| 98 36367 |
Dead | 72 | Male | 37.5 | 88 | 22 | 2 | Ruxolitinib 10 mg pd | 19 |
| 101 37339 |
Dead | 63 | Male | 36.9 | 80 | 25 | 4 | Tocilizumab 400 mg CVVH 1520 min |
30 |
| 114 37483 |
Alive | 79 | Male | 36.7 | 92 | 22 | 3 | Baricitinib 4 mg pd | - |
| 51 35875 |
Alive | 72 | Male | 38.0 | 92 | 22 | 4 | Tocilizumab 400 mg CVVH 1440 min |
- |
| 96 36891 |
Alive | 59 | Male | 37.6 | 86 | 27 | 4 | Tocilizumab 400 mg | - |
| 99 36444 |
Alive | 63 | Male | 36.6 | 88 | 21 | 4 | Tocilizumab 400 mg CVVH min 1490 min |
- |
| 126 37998 |
Alive | 74 | Male | 36.8 | 89 | 22 | 4 | Baricitinib 4 mg pd | - |
* CT-SKAN scores depending on the extent of consolidation or ground-glass opacities: 1—<25%; 2—25–50%; 3—50–75%; 4—>75%.